Barclays PLC Buys 143,072 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Barclays PLC increased its stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 187.6% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 219,331 shares of the biotechnology company’s stock after buying an additional 143,072 shares during the period. Barclays PLC owned 0.15% of Aurinia Pharmaceuticals worth $1,607,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Banque Cantonale Vaudoise boosted its holdings in shares of Aurinia Pharmaceuticals by 126.6% during the 2nd quarter. Banque Cantonale Vaudoise now owns 9,684 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 5,410 shares during the last quarter. CWM LLC lifted its position in Aurinia Pharmaceuticals by 247.7% during the third quarter. CWM LLC now owns 11,483 shares of the biotechnology company’s stock valued at $84,000 after purchasing an additional 8,180 shares during the period. FMR LLC boosted its holdings in Aurinia Pharmaceuticals by 44.8% in the third quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock worth $93,000 after purchasing an additional 3,919 shares during the last quarter. B. Riley Wealth Advisors Inc. bought a new position in Aurinia Pharmaceuticals in the second quarter valued at about $84,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Aurinia Pharmaceuticals by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 27,502 shares of the biotechnology company’s stock valued at $202,000 after buying an additional 10,700 shares during the last quarter. Institutional investors own 36.83% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on AUPH shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $10.00 price target on shares of Aurinia Pharmaceuticals in a research note on Monday, September 16th. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 target price on shares of Aurinia Pharmaceuticals in a report on Friday, September 6th. Finally, StockNews.com lowered Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 13th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Aurinia Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Aurinia Pharmaceuticals Trading Down 0.5 %

Aurinia Pharmaceuticals stock opened at $9.20 on Friday. Aurinia Pharmaceuticals Inc. has a 1 year low of $4.71 and a 1 year high of $10.67. The firm’s 50 day moving average price is $8.46 and its 200-day moving average price is $7.00. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. The stock has a market cap of $1.32 billion, a P/E ratio of -61.33 and a beta of 1.41.

Insider Activity at Aurinia Pharmaceuticals

In related news, Director Jeffrey Allen Bailey sold 4,557 shares of the business’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $8.43, for a total value of $38,415.51. Following the sale, the director now directly owns 13,356 shares in the company, valued at approximately $112,591.08. The trade was a 25.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.30% of the stock is currently owned by corporate insiders.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.